Clinical trial · Interventional
SIL as Maintenance Therapy in Multiple Myeloma
Selinexor Combined With Ixazomib and Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma
NCT06744894CI-TRIAL-00083977not yet recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this phase 2 trial is to test the safety and efficacy of selinexor combined with ixazomib and lenalidomide as maintenance therapy in patients with multiple myeloma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Selinexor combined with Ixazomib and Lenalidomide as Maintenance Therapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Maintenance Therapy
- description
- Patients were treated by Selinexor combined with Ixazomib and Lenalidomide as Maintenance Therapy
- interventionNames
- Drug: Selinexor combined with Ixazomib and Lenalidomide as Maintenance Therapy
Primary outcomes (1)
- measure
- PFS
- timeFrame
- 2 years
- description
- PFS was defined as the time from study entry until disease progression
Secondary outcomes (2)
- measure
- EFS
- timeFrame
- 2 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 14 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically confirmed Multiple Myeloma according World Health Organization (WHO) classification; * Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF). * Patient must understand and voluntarily sign an ICF prior to any study-specific assessments/procedures being conducted; * Patient is willing and able to adhere to the study visit schedule and other protocol requirements; * Documented response to ASCT (PR, VGPR, CR/stringent complete response \[sCR\]) according to IMWG criteria. Exclusion Criteria: * Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment. * Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy. * Pregnant or lactating women
References
Publications (0)
Data not yet available
No reference posted for this study.